Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Devel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Devel

Aurinia Pharmaceuticals (AUPH) PT Raised to $9 at RBC Capital

November 11, 2024 6:20 AM EST

RBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $9.00 (from $8.00) while maintaining a Outperform rating.

The analyst comments "Aurinia's Q3/24 product revenues of $55.5MM (+36% y/y) were ~2% ahead of estimates. Management reiterated its 2024 LUPKYNIS net revenue... More